---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-001913"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:27:45.436816+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reviva gets Nasdaq extension to March 27, 2026 for minimum bid price rule compliance

## Summary
- Nasdaq Panel granted exception through March 27, 2026 to regain compliance with $1.00 minimum bid price.
- Company requested hearing after delisting determination on Nov 11, 2025; hearing held Jan 8, 2026.
- To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.
- Company may implement reverse stock split if needed; warns split may not maintain price increase.
- Risk of delisting remains if unable to meet deadline or other Nasdaq listing requirements.

## SEC filing metadata
- accession: 0001437749-26-001913
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/rvph20260122_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-001913
- JSON: https://secwatch.observer/filing/0001437749-26-001913.json
- Plain text: https://secwatch.observer/filing/0001437749-26-001913.txt

## Source-grounded claims
- claim_id: 9454559ae2cda0ec3b64e57c6e93413683146749
  claim: REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2)).
  evidence_excerpt: January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/0001437749-26-001913-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.